Nykode Therapeutics (NYKD) 9th ASIT 2026 presentation summary

Strategic focus and platform overview

• Specializes in antigen-specific precision immunotherapy, targeting antigens to APCs for tailored immune responses in oncology and autoimmune diseases.

• Lead programs include a Phase 2 trial in head & neck cancer, individualized cancer immunotherapy, and preclinical autoimmune disease assets.

• Proprietary APC-targeting technology enhances T cell activation or induces immune tolerance by modulating Treg, effector T, and B cells.

• Modular platform design allows for targeting, antigen, and modulatory units to deliver antigen-specific immune tolerance.

• Multiple patent applications filed for platform innovations.

Preclinical and translational data

• Demonstrated strong preclinical efficacy in autoimmune models, including EAE (multiple sclerosis), NOD (type 1 diabetes), and vitiligo.

• APC-targeted therapies outperform non-targeted approaches in disease protection, Treg induction, and reduction of effector T and B cell responses.

• Durable disease amelioration and reduced CNS-infiltrating cells observed in symptomatic mice.

• Therapy reduces autoantibodies and pathogenic T cell responses in relevant models.

• Efficacy achieved with both intravenous and subcutaneous delivery routes.

Platform differentiation and AI-driven design

• Discovery of novel APC targets using human-relevant datasets and scRNA-seq enables selective engagement of tolerogenic APCs.

• AI/ML-driven framework accelerates multi-antigen construct design, with high in silico-to-experimental success rates.

• Multi-antigen constructs successfully designed and expressed across autoimmune indications.

• Human APC binding and immune modulation validated in vitro, supporting translational readiness.